Biocon is currently trading at Rs. 412.40, up by 4.80 points or 1.18% from its previous closing of Rs. 407.60 on the BSE.
The scrip opened at Rs. 409.90 and has touched a high and low of Rs. 415.00 and Rs. 406.50 respectively. So far 63849 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 487.70 on 23-Dec-2020 and a 52 week low of Rs. 235.80 on 19-Mar-2020.
Last one week high and low of the scrip stood at Rs. 415.00 and Rs. 399.85 respectively. The current market cap of the company is Rs. 49464.00 crore.
The promoters holding in the company stood at 60.67%, while Institutions and Non-Institutions held 23.68% and 15.65% respectively.
Biocon’s subsidiary--Biocon Biologics has entered into partnership with the International Diabetes Federation (IDF) as the first biosimilar insulin company to promote and support IDF’s Core Mission initiative and activities. This important partnership with IDF coincides with the start of the centenary celebrations of the discovery of insulin and takes forward Biocon Biologics’ mission of enabling affordable access to insulins to people with diabetes worldwide.
As a credible, global insulins player, having served more than 2 billion doses of human insulin till date, Biocon Biologics has been engaging with key stakeholders at various global forums to find ways to increase affordable access to insulin and ensure the therapy reaches those who need them the most.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
